Vermillion Performs an Estimated 6,155 OVA1 Tests in 2010 | GenomeWeb

Vermillion this week announced it had performed an estimated 2,935 OVA1 ovarian cancer tests during the fourth quarter ended Dec. 31, 2010 and an estimated 6,155 tests in all of 2010.

The fourth-quarter sales number represented a 48.8 percent increase over the third quarter of 2010, the company said in a statement, and the full-year 2010 figure of 6,155 exceeded the company's adjusted 2010 guidance of 5,000 to 5,500 tests, although it fell short of its initial 8,000 to 10,000 test guidance.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.